Abstract: A helical turbine with a circular member attached to one end for redirecting axially flowing fluid into perpendicularly flowing fluid. A fluid diverter for redirecting substantially perpendicular flowing fluid into axially flowing fluid. A hollow circular member attached to an opposite end of the turbine allowing substantially axial flowing fluid into one end of turbine. A drive shaft of at least one generator is in continuous contact with the peripheral edge of the solid or hollow circular member producing faster rpm. A turbine assembly mounted on a rooftop utilizing accelerated wind. Fluid diverters increasing fluid flow into the helical turbine's receding blades. A fluid diverter preventing fluid from hitting turbine's oncoming blades. A tail section for maintaining optimal direction into oncoming fluid. Two counter rotating turbines where the attached circular member's edges are in continuous contact.

Abstract: A method for inhibiting the action of TNF for treating neurological conditions in a human by administering a TNF antagonist for reducing the inflammation of neuronal tissue of said human, or for modulating the immune response affecting neuronal tissue of said human, comprising the step of: administering a therapeutically effective dosage level to said human of said TNF antagonist selected from the group consisting of etanercept, infliximab, and D2E7 (a human anti-TNF mAb from Knoll Pharmaceuticals) for reducing the inflammation of neuronal tissue of said human, or for modulating the immune response affecting neuronal tissue of said human. In addition, for the viral-associated neurological disorders, the following additional step is performed: administering a therapeutically effective dosage level to said human of an antiviral agent or anti-retroviral agents for reducing the inflammation of neuronal tissue of said human, or for modulating the immune response affecting neuronal tissue of said human.